GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (NAS:REGN) » Definitions » Forward Rate of Return (Yacktman) %

REGN (Regeneron Pharmaceuticals) Forward Rate of Return (Yacktman) % : 8.87% (As of Mar. 2025)


View and export this data going back to 1991. Start your Free Trial

What is Regeneron Pharmaceuticals Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Regeneron Pharmaceuticals's forward rate of return for was 8.87%.

The historical rank and industry rank for Regeneron Pharmaceuticals's Forward Rate of Return (Yacktman) % or its related term are showing as below:

REGN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 9.11   Med: 22.52   Max: 24.48
Current: 10.16

During the past 13 years, Regeneron Pharmaceuticals's highest Forward Rate of Return was 24.48. The lowest was 9.11. And the median was 22.52.

REGN's Forward Rate of Return (Yacktman) % is ranked better than
59.26% of 162 companies
in the Biotechnology industry
Industry Median: 3.96 vs REGN: 10.16

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Regeneron Pharmaceuticals Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Regeneron Pharmaceuticals's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Forward Rate of Return (Yacktman) % Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.71 23.60 23.75 23.48 11.98

Regeneron Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.16 18.62 14.65 11.98 8.87

Competitive Comparison of Regeneron Pharmaceuticals's Forward Rate of Return (Yacktman) %

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals's Forward Rate of Return (Yacktman) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Forward Rate of Return (Yacktman) % falls into.


;
;

Regeneron Pharmaceuticals Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Regeneron Pharmaceuticals's Forward Rate of Return of Mar. 2025 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=33.33085714/634.23+0.0361
=8.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regeneron Pharmaceuticals  (NAS:REGN) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Regeneron Pharmaceuticals Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals Business Description

Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Executives
Marion Mccourt officer: SVP Commercial C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Arthur F Ryan director CITIZENS FINANCIAL GROUP, INC, 600 WASHINGTON BOULEVARD, STAMFORD CT 06901
Christopher R. Fenimore officer: VP, Controller REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Bonnie L Bassler director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Christine A Poon director C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Andrew J Murphy officer: EVP Research REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Neil Stahl officer: SVP, Preclinical Development 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Joseph J Larosa officer: SVP Gen Counsel & Secretary 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Michael S Brown director
Leonard S Schleifer director, officer: President & CEO 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
George Yancopoulos director, officer: President and CSO 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
George L Sing director LANCET CAPITAL, 45 ROCKEFELLER PLAZA STE 2008, NEW YORK NY 10111
Van Plew Daniel P officer: EVP & General Mgr Industrial O REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Joseph L Goldstein director DEPT OF PHARMACOLOGY K5 YUVER OF TEXAS, 5323 HARRY HINES BLVD, DALLAS TX 75390
Huda Y Zoghbi director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591

Regeneron Pharmaceuticals Headlines